What is UBS's current rating and price target for Linde, and what key business areas does it cite as central to its outlook?

UBS has reiterated its Buy rating and $612 price target for Linde plc (NASDAQ:LIN), citing the company's strategic management of challenges in its healthcare (Lincare) and helium businesses as central to its positive outlook.

According to UBS, what earnings growth trajectory does Linde expect through 2027, and what factors are driving it despite current valuation concerns?

UBS anticipates strong double-digit earnings per share growth for Linde through 2027, driven by improving volumes and backlog contributions — even though InvestingPro data currently indicates the stock appears overvalued.

UBS Reaffirms $612 Price Target for Linde on Cost Cuts

Sep 4, 2026

UBS reaffirmed a $612 price target for Linde, citing cost cuts and strategic management of healthcare and helium segments. The bank expects strong double-digit earnings growth through 2027 despite some margin concerns.

Investing.com India

Linde stock price target reaffirmed at $612 by UBS on cost cuts

Investing.com UK

Linde stock price target reaffirmed at $612 by UBS on cost cuts

Investing.com Nigeria

Show all reports

2026-04-08

Asio Capital LLC Increases Stake in Linde PLC

2026-04-08

Yousif Capital Management LLC Sells 2,739 Shares of Linde PLC

2026-04-09